HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.9%

Neg 0% Neu 91.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $345 price target.